imatinib mesylate has been researched along with Leukemia, Myelomonocytic, Acute in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SN; Dai, HP; Gong, YL; Pan, JL; Wu, DP; Wu, LL; Wu, YF; Xue, YQ; Zhang, J | 1 |
| Bessho, M; Ito, K; Jinnai, I; Suzuki, T; Tominaga, K | 1 |
| Arai, Y; Mitani, K; Tadokoro, J; Takahashi, W; Takeuchi, K; Yamagata, T | 1 |
3 other study(ies) available for imatinib mesylate and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Combined Modality Therapy; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Male; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2012 |
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
[Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
Topics: Benzamides; Clone Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Acute; Middle Aged; Piperazines; Pyrimidines | 2006 |